Toripalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, Toripalimab is a humanized monoclonal antibody that targets programmed death receptor 1 (PD-1). It is used to treat patients with unresectable or metastatic melanoma who have previously failed systemic therapy. It is intended for treatment Breast cancer, lymphoma, malignant melanoma, genitourinary system cancer and other types of solid tumors.
Biosimilars
Human
Monoclonal
Human
PDCD1/PD1/CD279
Human
IgG4 Kappa
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
CAS Number 1924598-82-2
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más